Jan 22 (Reuters) - Teva Pharmaceutical Industries said on Monday two late-stage studies testing its treatment for asthma did not meet their main goals.
The studies were testing Teva's subcutaneous dosing of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils.
The drug is already approved as an intravenous shot to treat patients with severe asthma.
(Reporting by Manas Mishra in Bengaluru; Editing by Martina D'Couto)
Tesla's loss of $328.3 billion this year in stock value certainly hurts. But it's only the second-largest market value loss in the S&P 500.
On paper, Mark Zuckerberg is Meta’s lowest-paid employee, with a $1 dollar salary and no bonus.
This growth ETF has nicely outperformed the S&P 500 since its inception.
You'll only find seven different stocks in this billionaire's portfolio, and only one of them is a "big tech" company.
Bitcoin block subsidies were recently reduced by half for the fourth time in history, and halving events have always led to significant price appreciation.
Microsoft, which overtook Apple as the world's most valuable company earlier this year, is looking to cement its AI market leadership.
With rising inflation, American consumers are increasingly turning to the Chinese e-commerce platform Temu for their shopping needs. With its enticing tagline “Shop like a billionaire,” Temu has captured 17% of the U.S. market share, posing a challenge to traditional American retailers such as Amazon.com Inc., Dollar Tree Inc. and Five Below Inc. The rise highlights the lucrative and disruptive nature of startups. Owned and operated by PDD Holdings Inc. (NASDAQ:PDD), Temu offers a wide range of
One of Capitol Hill's most-active stock traders is sending a company with well-defined competitive advantages -- that also happens to be on the verge of its first-ever stock split -- to the chopping block.
These stocks all deserve to be trading at far higher prices, and it may not be too long before they start to rally.
This stock is reasonably priced, even after explosive gains.